Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 in Advanced Gynecological Tumors
NCT06834542Phase 1Terminated
- Sponsor
- Grit Biotechnology
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT201 in Cervical Cancer (CC), sponsored by Grit Biotechnology. Primary endpoints: Objective Response Rate at 3 years, Incidence and severity of adverse events per CTCAE 5.0 at 3 years and 1 more. Started Nov 2022; status: terminated.
02
Drugs
GT201
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06834542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834542.